ANGUANA BIOTECH.
Executive Summary
www.anguana.de
info@anguana.de
The Problem
Modern healthcare is paralyzed by an infrastructure bottleneck. Biologics and antimicrobials depend on a fragile "cold chain" and centralized factories that fail 70% of the time in the "last mile."
Every fifth death worldwide is caused by Sepsis. In total 13.7M people die annually from Sepsis, including 4.95 million deaths associated with antimicrobial resistance (AMR), exacerbated by the fact that shelf-stable therapeutics cannot survive without continuous refrigeration in conflict zones and low-resource settings.
The Solution
Anguana Biotech decouples medicine from the factory. Our platform utilizes a proprietary carbohydrate matrix to protect DNA blueprints and synthesis machinery in extreme heat (50°C+).
We provide a 1000x preservation advantage, enabling on-demand synthesis at the point of care with zero refrigeration. No comparable decentralized synthesis platforms currently exist on the market.
Vision
Enabling the synthesis of critical therapeutics at the point of care, eliminating 100% of refrigeration requirements and reducing costs by 10x compared to centralized logistics.
Technology
As drug delivery system (DDS) we optimised a cell-free protein synthesis (CFPS) platform to preserve its biosynthesis capabilities through storage at room temperature for longer periods of time. To prevent sepsis and actively support with wound healing the platform synthesis once activated Antimicrobial peptides. It has been shown that 2μg of these AMP can significantly lower the risk of lethal sepsis. Moreover the platform is designed to be extreme low cost with resulting material costs of 0.021$/μg protein in order to ensure affordability.
Stability Benchmark (RT % Yield)
Strategic Advantage
TAM 2028
Logistics Freedom
Advisory
Prof. Dr. Friedrich Simmel
Chair of Experimental Physics, TUM
"Lead researcher in bionanotechnology and the physics of synthetic biological systems. Focuses on artificial molecular machines and DNA nanostructures. Member of acatech."
Prof. Dr. Bastian Blombach
Prof. of Microbial Biotechnology, TUM
"Expert in metabolic engineering and systems biology. Specializes in optimizing microbial production processes and constructing tailor-made cell factories for industrial biotechnology."
Team
Tamás Kotán
Business Development Lead
Student at Technical University of Munich, Venture Scout at First Momentum, and Software Engineer at the Center of Molecular Fingerprinting.
Pascal Mayer
Technical Lead
Student in Molecular Biotechnology at TU München and currently active at TUM VL FAB. Brings extensive laboratory experience in microbiology, biochemistry, and quantitative analysis to the field of synthetic biology.
Samantha Krumdiek
Operative Lead
Student in Management & Technology at TU München with a strong focus on business development, strategy, and entrepreneurship. Experience in strategic and operative decision-making.
Strategic Scaling Roadmap
FOUNDATION
Securing laboratory space and institutional support at TUM. Completion of strategic ideation, market positioning, and stakeholder consultation.
POC & PATENTING
Accelerated development of proof-of-concept prototypes. Securing robust intellectual property filings for the core stabilization matrix.
SECURING INVESTMENTS
Establishing B2B licensing partnerships with pharma leaders. Opening Series A funding to fuel clinical validation and field trials.
OWN PIPELINE
Commercializing proprietary therapeutic product lines and scaling decentralized use-cases across global health markets.